Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV: RP)

Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV:
                                     RP)

PR Newswire

TORONTO, June 19, 2014

TORONTO, June 19, 2014 /PRNewswire/ - Ubika Research has recently published a
new information report on RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB:
REPCF), a regenerative medicine company focused on developing autologous cell
therapies for multi-billion dollar markets that address diseases caused by a
deficit of healthy cells required for normal healing and function, such as
chronic tendinosis, damaged skin and pattern baldness.

Read the report here:
http://www.smallcappower.com/reports/files/replicel-life-sciences-inc-research-report

About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing autologous
cell therapies that address diseases caused by a deficit of healthy cells
required for normal healing and function such as chronic tendinosis, damaged
skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies are
designed to treat chronic tendinosis and damaged or aging skin respectively,
using fibroblasts isolated from the sheath of the hair follicle.

Another of the company's pipeline products, RCH-01 for the treatment of
pattern baldness, is manufactured from cells derived from the hair follicle
dermal cup. Shiseido Company, Limited has an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South Korea. All
product candidates are based on RepliCel's innovative technology, which
utilizes cells isolated from a patient's own healthy hair follicles to address
specific cellular deficits. For additional information please
visitwww.replicel.com.

To view the initiation research report, research bulletins, analyst
commentaries and CEO video interview please
visit:http://www.smallcappower.com/companies/products/replicel-life-sciences-tsxv-rp

About Ubika Research

Ubika Research is an investment research and capital market services firm
based in Toronto with a proven track record of identifying and launching
coverage of high potential small cap stocks (<$5 billion) at an early stage.
For more information visit www.ubikaresearch.com

Disclosure

Ubika Research has received compensation from RepliCel Life Sciences Inc. to
provide analyst research coverage.

Except for the historical information presented herein, matters discussed in
this document contain forward-looking statements that are subject to certain
risks and uncertainties that could cause actual results to differ materially
from any future results, performance or achievements expressed or implied by
such statements.

Ubika Research andwww.smallcappower.com(are both divisions of Ubika
Corporation), and are not registered with any financial or securities
regulatory authority, and does not provide nor claims to provide investment
advice or recommendations to readers of this report. For making specific
investment decisions, readers should seek their own advice. For full
disclosure please visit:
http://www.smallcappower.com/posts/small-cap-power-disclosure.

SOURCE Ubika Research

Contact:

Vikas Ranjan, Managing Director, Email:vikas@ubikacorp.com
 
Press spacebar to pause and continue. Press esc to stop.